BiotechTube

HRS-9190

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Skeletal Muscle Relaxation

Conditions

Skeletal Muscle Relaxation

Trial Timeline

Aug 26, 2025 → Oct 31, 2025

NCT ID
NCT07142850

About HRS-9190

HRS-9190 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Skeletal Muscle Relaxation. The current trial status is completed. This product is registered under clinical trial identifier NCT07142850. Target conditions include Skeletal Muscle Relaxation.

What happened to similar drugs?

1 of 3 similar drugs in Skeletal Muscle Relaxation were approved

Approved (1) Terminated (0) Active (2)
✅LumiracoxibNovartisApproved
🔄Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
🔄Botulinum toxin type AIpsenPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07142850Phase 1Completed

Competing Products

9 competing products in Skeletal Muscle Relaxation

See all competitors
ProductCompanyStageHype Score
Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
40
No interventionJohnson & JohnsonPre-clinical
26
HRS-9190 for InjectionJiangsu Hengrui MedicinePhase 1
29
ACE-083MerckPhase 1
29
BYM338 + PlaceboNovartisPhase 2
35
LumiracoxibNovartisApproved
43
Nerve Growth FactorLundbeckPre-clinical
15
Botulinum toxin type AIpsenPhase 3
37
BurosumabUltragenyx PharmaceuticalPhase 1
19